Advertisement

Topics

Ligand to receive $2m from WuXi for licensing clinical-stage anti-PD-1 antibody

07:19 EDT 21 Aug 2017 | Pharmaceutical Business Review

Ligand Pharmaceuticals will get a payment of $2m from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and other selected territories.

Original Article: Ligand to receive $2m from WuXi for licensing clinical-stage anti-PD-1 antibody

NEXT ARTICLE

More From BioPortfolio on "Ligand to receive $2m from WuXi for licensing clinical-stage anti-PD-1 antibody"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...